Julie Brahmer, MD
Medical Oncology · Baltimore, MDNPI 1982661989
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $126,134 of the $134,625 with a category attached, or 93.7%. It is spread thinly across 23 manufacturers, the largest accounting for just 16.3%. Among medical oncology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $1060.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- AstraZeneca$18K
- GSK$14K
- E.r. Squibb & Sons, L.L.C.$12K
- Bayer$10K
- Astrazeneca UK Limited$10K
- plus $48K from 17 others
Across 94 payments — averaging $20,322 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$918K
- AstraZeneca$394K
- Merck$239K
- Incyte Corporation$198K
- Astrazeneca UK Limited$70K
- Janssen Research & Development, LLC$34K
- plus $57K from 3 others
What the payments were for
- Consulting fees$126,13494%
- Speaking & faculty fees$3,5003%
- Travel & lodging$2,3492%
- Food & beverage$2,6412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $21,944 |
| AstraZeneca | 29 | $18,489 |
| GSK | 8 | $13,815 |
| E.r. Squibb & Sons, L.L.C. | 8 | $12,165 |
| Bayer | 10 | $10,407 |
| Astrazeneca UK Limited | 8 | $10,029 |
| Merck | 4 | $8,750 |
| Sanofi-aventis U.S. LLC | 9 | $8,541 |
| Sanofi | 2 | $5,087 |
| Janssen Scientific Affairs, LLC | 2 | $4,195 |
| Incyte Corporation | 1 | $3,075 |
| Genentech USA, Inc. | 7 | $2,466 |
| Bristol Myers Squibb | 1 | $2,400 |
| Daiichi Sankyo Inc. | 2 | $2,317 |
| Janssen Research & Development, LLC | 2 | $1,890 |
| Eisai Inc. | 1 | $1,875 |
| Johnson & Johnson(2 entities) | 6 | $1,852 |
| Foundation Medicine, Inc. | 1 | $1,750 |
| Eli Lilly | 2 | $1,437 |
| Regeneron Healthcare Solutions, Inc. | 1 | $1,310 |
| Janssen Global Services, LLC | 1 | $625 |
| Astrazeneca AB | 6 | $133 |
| Pfizer | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,625 in reported general payments places this provider in the 90th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 30 | $618,681 |
| LumakrasSotorasib | 17 | $208,737 |
| AlecensaAlectinib Hcl | 13 | $174,634 |
| Prochlorperazine Maleate | 24 | $220 |
| Dexamethasone | 13 | $204 |
| Pantoprazole Sodium | 11 | $104 |
| Folic Acid | 13 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $18,489 | $618,68130 claims |
| AmgenLumakras | $21,944 | $208,73717 claims |
| Genentech USA, Inc.Alecensa | $2,466 | $174,63413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.